AbCellera Biologics (ABCL) Stock Price, News & Analysis

Company Overview

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. Leveraging a proprietary single-cell screening platform, advanced microfluidics, and machine learning algorithms, the company accelerates the identification of antibody candidates against a broad range of disease targets. Its technology aims to streamline early‐stage drug discovery by rapidly isolating potent and specific antibodies from natural immune responses.

Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera has built a high-throughput laboratory infrastructure to support its antibody discovery efforts. The company emerged from academic research at the University of British Columbia, translating cutting-edge immunology and bioengineering into a commercial platform. Over the years, it has expanded its R&D capabilities with additional facilities in the San Francisco Bay Area, strengthening its presence in both Canadian and U.S. biotech hubs.

AbCellera’s services include antigen assay development, single-cell screening, lead optimization and antibody engineering. The company collaborates with pharmaceutical and biotechnology partners to co-develop therapeutics against infectious diseases, oncology, immunology and other areas of unmet medical need. Notably, AbCellera formed a high-profile partnership with Eli Lilly to develop bamlanivimab, a neutralizing antibody for COVID-19, demonstrating its capacity to respond to global health challenges on accelerated timelines.

Serving clients across North America, Europe and Asia, AbCellera maintains strategic alliances with both large pharmaceutical companies and emerging biotech firms. Under the leadership of co-founder and CEO David J. Johnston, the company continues to invest in artificial intelligence and automation to enhance throughput and data analytics. As it scales its proprietary platform, AbCellera aims to remain at the forefront of antibody discovery, enabling partners to bring innovative biologic therapies to market more efficiently.

Key Stats

• Today's Range: $3.66 to $3.81
• 50-Day Range: $1.97 to $3.81
• 52-Week Range: $1.89 to $4.09
• Volume: 1.95 million shs
• Average Volume: 3.41 million shs
• Market Capitalization: $1.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.33
• Consensus Rating: Moderate Buy

AbCellera Biologics Stock Analysis - MarketRank™

AbCellera Biologics scored higher than 50% of companies evaluated by MarketBeat, and ranked 535th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

AbCellera Biologics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbCellera Biologics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbCellera Biologics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AbCellera Biologics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.84% of the float of AbCellera Biologics has been sold short.

Short Interest Ratio / Days to Cover

AbCellera Biologics has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in AbCellera Biologics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AbCellera Biologics does not currently pay a dividend.

Dividend Growth

AbCellera Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.84% of the float of AbCellera Biologics has been sold short.

Short Interest Ratio / Days to Cover

AbCellera Biologics has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in AbCellera Biologics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

AbCellera Biologics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for AbCellera Biologics this week, compared to 3 articles on an average week.

Search Interest

20 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 54% compared to the previous 30 days.

MarketBeat Follows

6 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.90% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABCL Stock Analysis - Frequently Asked Questions

How have ABCL shares performed this year?

AbCellera Biologics' stock was trading at $2.93 at the beginning of 2025. Since then, ABCL shares have increased by 29.9% and is now trading at $3.8050.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) released its earnings results on Thursday, May, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. The company earned $4.24 million during the quarter, compared to analysts' expectations of $7.12 million. AbCellera Biologics had a negative net margin of 737.56% and a negative trailing twelve-month return on equity of 15.98%.
Read the conference call transcript.

When did AbCellera Biologics IPO?

AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AbCellera Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABCL
• CIK: 1703057
• Web: www.abcellera.com
• Phone: 604-559-9005
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.33
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +119.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$162.86 million
• Net Margins: -737.56%
• Pretax Margin: -911.23%
• Return on Equity: -15.98%
• Return on Assets: -12.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.15
• Quick Ratio: 10.15

Sales & Book Value

• Annual Sales: $28.83 million
• Price / Sales: 39.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.58 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 298,420,000
• Free Float: 212,179,000
• Market Cap: $1.14 billion
• Optionable: Optionable
• Beta: 0.62